This is a working overview of triple agonist, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-04-25 and is reviewed periodically as new material appears.
Development has progressed from single- and multiple-ascending-dose studies in healthy volunteers into larger randomized trials in adults with obesity, type 2 diabetes, and fatty liver disease. Early reports describe dose-dependent reductions in body weight and improvements in glycemic markers over treatment periods of several months. Whether the glucagon arm adds tolerability cost without added benefit is still debated. Long-term cardiovascular outcomes, effects after treatment stops, and performance in older or comorbid populations are open questions rather than settled findings. Approval status may change, so the current investigational label should be confirmed against regulatory sources.
Retatrutide is an investigational synthetic peptide developed under the code LY3437943, with a backbone derived from glucose-dependent insulinotropic polypeptide. Several non-proteinogenic residues, including alpha-aminoisobutyric acid, appear in that backbone, and a fatty diacid side chain attached through a linker extends circulation time. The molecule carries roughly thirty-nine amino acid units and a total mass near 4.7 kilodaltons. Administration is by subcutaneous injection once weekly. Published work uses both the name retatrutide and the code LY3437943.
Pharmacologically the compound activates three receptors: GLP-1, GIP, and glucagon. GLP-1 and GIP signaling contribute to glucose-dependent insulin release, delayed gastric emptying, and reduced appetite, while glucagon receptor activation is associated with increased energy expenditure and hepatic fat oxidation. The single-molecule design is intended to keep these activities in one peptide rather than combining separate agents. Relative activity at each receptor differs, and the balance between them is a central question in interpretation. The glucagon component is partly offset by incretin-mediated insulin secretion, an interaction that remains incompletely characterized.
Published information places retatrutide in clinical development rather than on the market as an approved therapy. Early-stage and mid-stage trials have examined tolerability and changes in body weight, and larger studies continue to report results over time. Open questions include the durability of effects after treatment stops, the composition of weight lost, and cardiovascular outcomes over long periods. Statements about definitive benefit should therefore be treated as provisional. Regulatory status varies by jurisdiction and changes as applications are reviewed.
Retatrutide is an investigational synthetic peptide designed to activate three distinct receptor systems within a single molecule. Its pharmacological profile combines activity at the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This arrangement places it within a broader class of agents often described as multi-agonists, which contrast with compounds that engage one or two targets. Research interest centers on whether simultaneous signaling produces effects that single-receptor agonists cannot achieve alone. A single molecular entity also simplifies manufacturing and delivery logistics compared with combining separate agents.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide of about 39 residues | Backbone derived from a GIP sequence |
| Molecular mass | Approximately 4.7 kDa | Peptide chain plus fatty diacid moiety |
| Receptor targets | GLP-1, GIP, glucagon | Unimolecular triple agonist |
| Typical storage temperature | 2 to 8 degrees Celsius | Protect from light; avoid repeated freeze-thaw |
| Common analytical method | LC-MS/MS | Used for plasma quantification and purity checks |
Clinical studies have reported notable reductions in body weight among participants. Early trials measured safety and explored several dose levels, and later studies tracked body-weight change over months of treatment. Investigators also monitor effects on glycemic markers, liver fat, and blood lipids. Because the compound is still in development, questions about long-term safety, cardiovascular outcomes, and durability after treatment ends remain open.
The three-receptor design places retatrutide in a distinct category relative to older incretin-based therapies. Single agonists target one receptor, and dual agonists target two. Adding a third target broadens the pharmacological footprint and introduces new trade-offs among efficacy, tolerability, and glucose control. How these trade-offs resolve in large trials is a central focus of current research.
Retatrutide is an investigational peptide studied for obesity and type 2 diabetes. It is a single synthetic molecule designed to activate three metabolic receptors simultaneously. The compound belongs to the incretin mimetic family, a group of peptides that imitate gut hormones involved in appetite and glucose control. Its research code is LY3437943, and it remains under clinical study rather than cleared for routine medical use.
Several questions about the compound remain unresolved. The durability of weight reduction after treatment stops, the frequency of gastrointestinal side effects, and the long-term cardiovascular profile are topics of ongoing study. Regulatory submissions and phase 3 trial outcomes have not been fully reported in the public literature. Because most available data come from controlled trials rather than general-population use, conclusions about effectiveness outside study settings are provisional. The distinction between established findings and open questions matters when interpreting early coverage of the drug.
Retatrutide is an investigational peptide developed by a pharmaceutical company as a multi-receptor agonist for treating obesity and type 2 diabetes. The compound emerged from research into gut-hormone analogues that act on several receptors simultaneously rather than on a single target. Early preclinical work examined how combined activity at three distinct receptors might produce greater metabolic effects than single-receptor compounds. Published phase 2 results have described substantial reductions in body weight among participants, although the compound remains unapproved in most jurisdictions as of the mid-2020s.
where Ni is the number of molecules of molecular mass Mi. The mass average molecular mass can be determined by static light scattering, small angle neutron scattering, X-ray scattering, and sedimentation velocity. The ratio of the mass average to the number average is called the dispersity or the polydispersity index. The mass-average molecular mass, Mw, is also related to the fractional monomer conversion, p, in step-growth polymerization (for the simplest case of linear polymers formed from two monomers in equimolar quantities) as per Carothers' equation:
3-hydroxydecanoyl-(acyl-carrier-protein) dehydratase (EC 4.2.1.60, D-3-hydroxydecanoyl-[acyl-carrier protein] dehydratase, 3-hydroxydecanoyl-acyl carrier protein dehydrase, 3-hydroxydecanoyl-acyl carrier protein dehydratase, β-hydroxydecanoyl thioester dehydrase, β-hydroxydecanoate dehydrase, beta-hydroxydecanoyl thiol ester dehydrase, FabA, β-hydroxyacyl-acyl carrier protein dehydratase, HDDase, β-hydroxyacyl-ACP dehydrase, (3R)-3-hydroxydecanoyl-[acyl-carrier-protein] hydro-lyase) is an enzyme with systematic name (3R)-3-hydroxydecanoyl-(acyl-carrier protein) hydro-lyase. This enzyme catalyses the following chemical reaction
In 2012, a laser engraved panel featuring Wheatley was launched aboard the Japan Aerospace Exploration Agency (JAXA)'s Kounotori 3 mission on its way to resupply the International Space Station. In April 2011, series of Portal-themed DLC levels were added to the game The Ball. A few Portal characters, including Chell and P-Body, feature as avatar customization items in the game Fall Guys for 5 crowns each. The portal gun is one of several weapons used alongside ones from other game and film franchises in a climactic fight for the 2021 film Free Guy which takes place within a video game. A reference to GLaDOS appears in a sub-quest in Cyberpunk 2077 as a murderous AI driving a taxi and eventually tries to kill the protagonist. In 2022, GEICO released a commercial entitled "The Gecko Visits Portal", featuring elements from the Portal games such as an unreleased test chamber shown in trailers for Portal 2, with McLain reprising her role as GLaDOS. Rocket League released free DLC that includes a variety of items from the Portal series available for vehicle customization. Evil Genius 2: World Domination includes a free Portal themed expansion pack which adds Portal-themed rooms and traps to the game. Escape Simulator features a free Portal Escape Chamber DLC in which players will need to escape from the Aperture Science Laboratories by solving various puzzles.
== History == The safety and effectiveness of dulaglutide were evaluated in six clinical trials in which 3,342 subjects with type 2 diabetes received dulaglutide. Subjects receiving dulaglutide had an improvement in their blood sugar control as observed with reductions in HbA1c level (hemoglobin A1c is a measure of blood sugar control). The US Food and Drug Administration (FDA) approved dulaglutide with a Risk Evaluation and Mitigation Strategy (REMS), and granted the approval of Trulicity to Eli Lilly and Company. The REMS consists of a number of steps that Eli Lilly will take to make physicians aware of the risk of pancreatitis and the potential risk of medullary thyroid carcinoma associated with the drug. In 2020, the FDA approved two higher doses of the medication, 3.0 mg and 4.5 mg, based on results of the AWARD-11 trial demonstrating improved glucose lowering and weight benefits.
Although there is a theoretical yield of 38 ATP molecules per glucose during cellular respiration, such conditions are generally not realized because of losses such as the cost of moving pyruvate (from glycolysis), phosphate, and ADP (substrates for ATP synthesis) into the mitochondria. All are actively transported using carriers that utilize the stored energy in the proton electrochemical gradient.
Sources: en.wikipedia.org
In May 2013, Doug Matthews set an altitude record of 12,975 m (42,568 ft) in a P-51 named The Rebel for piston-powered aircraft weighing 3,000 to 6,000 kg (6,600 to 13,200 lb). Flying from a grass runway at Florida's Indiantown airport and over Lake Okeechobee, Matthews set world records for time to reach altitudes of 9,000 m (30,000 ft), 18 minutes and 12,000 m (39,000 ft), 31 minutes. He set a level-flight altitude record of 12,200 m (40,100 ft) in level flight and an absolute altitude record of 13,000 m (42,500 ft), breaking the previous record of 11,248 m (36,902 ft) set in 1954.
=== Exon 3 === Studies have identified a GHBP isoform that exists due to gene polymorphism, or variable expression of the allele. These isoforms differ based on whether or not the extracellular domain of GHR includes the amino acids encoded by exon 3 - exon 3 is either kept (dominant) or spliced out (recessive). As human are diploid, they may genotype as homozygous dominant (two copies of the allele retain exon 3), heterozygous (one copy with Exon 3, and one without), or homozygous recessive (two copies of the allele without exon 3). Studies have shown that the two isoforms can co-exist as dimerized GH receptors, as E3+/E3+, E3+/E3-, or E3-/E3-. Furthermore, the two isoforms both exist in the blood as GHBP. However, they may have separate functions that are poorly understood. The presence or absence of exon 3 in humans is individual-specific, but one study suggests that gender may play a role in this variable splicing, as females were shown to express higher levels of deleted-exon 3 GHBP in their blood. The evolutionary reason for exon-3 variable GHBP expression has not clearly be defined, and the isoforms in the blood have not been shown to differ with respect to GH affinity, which is unusual for an isoform that is missing an entire exon.
If an adsorbate molecule enters the precursor state at a location that is remote from any other previously adsorbed adsorbate molecules, the sticking probability is reflected by the size of the SD constant. These factors were included as part of a single constant termed a "sticking coefficient", kE, described below:
=== Notable applications === With the development of native chemical ligation in 1994, total chemical synthesis of pairs of D-protein and L-protein enantiomers became feasible. In the first practical application to solving an unknown structure, racemic and quasi-racemic X-ray crystallography were used to determine the structure of snow flea anti-freeze protein. In the course of that work it was observed that racemic and even quasi-racemic protein mixtures dramatically facilitated the formation of diffraction quality, centrosymmetric crystals. Quasi-racemates are formed by mirror image protein molecules that are not true enantiomers but which are sufficiently similar mirror image objects to form ordered pseudo-centrosymmetric arrays. Subsequently, pairs of racemic and quasi-racemic protein molecules prepared by total chemical synthesis have been shown to dramatically increase the rate of success in forming diffraction-quality crystals from a wide range of globular protein molecules. Rv1738, a protein of Mycobacterium tuberculosis is the most up-regulated gene product when M. tb enters persistent dormancy. Preparations of recombinantly expressed Rv1738 L-protein resisted extensive attempts to form crystals. A racemic mixture of the chemically synthesized D-protein and L-protein forms of Rv1738 gave crystals in the centrosymmetric space group C2/c. The structure, containing L-protein and D-protein dimers in a centrosymmetric space group, revealed structural similarity to 'hibernation-promoting factors' that can bind to ribosomes and suppress translation.
Sources: en.wikipedia.org
The mummies of the Canary Islands belong to the indigenous Guanche people and date to the time before 14th-century Spanish explorers settled in the area. All deceased people within the Guanche culture were mummified during this time, though the level of care taken with embalming and burial varied depending on individual social status. Embalming was carried out by specialized groups, organized according to gender, who were considered unclean by the rest of the community. The techniques for embalming were similar to those of the ancient Egyptians, involving evisceration, preservation, and stuffing of the evacuated bodily cavities, then wrapping the body in animal skins. Despite the successful techniques utilized by the Guanche, very few mummies remain due to looting and desecration.
=== Contraindications === Ketosis induced by a ketogenic diet should not be pursued by people with pancreatitis because of the high dietary fat content. Ketosis is also contraindicated in pyruvate carboxylase deficiency, porphyria, and other rare genetic disorders of fat metabolism.
Copurification in a chemical or biochemical context is the physical separation by chromatography or other purification technique of two or more substances of interest from other contaminating substances. For substances to co-purify usually implies that these substances attract each other to form a non-covalent complex such as in a protein complex. However, when fractionating mixtures, especially mixtures containing large numbers of components (for example a cell lysate), it is possible by chance that some components may copurify even though they don't form complexes. In this context the term copurification is sometimes used to denote when two biochemical activities or some other property are isolated together after purification but it is not certain if the sample has been purified to homogeneity (i.e., contains only one molecular species or one molecular complex). Hence these activities or properties are likely but not guaranteed to reside on the same molecule or in the same molecular complex.
Lee recalled that it was Danniels who deemed him "not suitable, for whatever reasons he had", but Lifeson noted that Rutsey, whose influential personality often steered the group, had pushed for a different bassist and went along with the decision. Following Lee's exit, Rutsey recruited bassist Joe Perna and renamed the band to Hadrian. However, after a poorly received performance with Perna, Rutsey and Lifeson invited Lee to rejoin in September 1969. Lee said: "I got a call from John and he said, 'Can we get together?' Basically, 'Can you come back? We're sorry.'" Young left the group to study at college; following brief tenures by second guitarist Bob Vopni in 1969 and rhythm guitarist Mitch Bossi in 1971, the lineup stabilised as a power trio of Lifeson, Rutsey and Lee by 1972. The group refined their live performances through extensive touring of the Ontario high school circuit. Drawing heavy influence from Led Zeppelin's debut album, Rush developed a blues-based hard rock sound characterised by Lee's increasingly high-register falsetto. During this period, Danniels struggled to secure consistent bookings as the band began prioritising original material over standard covers in their live sets. The band's professional trajectory shifted in 1971 following a legislative change that lowered Ontario’s legal drinking age from 21 to 18. This allowed the group to play bars and clubs, a move Lee described as the catalyst for their evolution from a "casual garage act" into a professional unit performing six nights a week.
Anarchy is a form of society without rulers. As a type of stateless society, it is commonly contrasted with states, which are polities that claim a monopoly on violence over a permanent territory. Beyond a lack of government, it can more precisely refer to societies that lack any form of authority or hierarchy. While viewed positively by anarchists, the primary advocates of anarchy, it is viewed negatively by advocates of statism, who see it in terms of social disorder. The word "anarchy" was first defined by Ancient Greek philosophy, which understood it to be a corrupted form of direct democracy, where a majority of people exclusively pursue their own interests. This use of the word made its way into Latin during the Middle Ages, before the concepts of anarchy and democracy were disconnected from each other in the wake of the Atlantic Revolutions. During the Age of Enlightenment, philosophers began to look at anarchy in terms of the "state of nature"; a thought experiment used to justify various forms of hierarchical government. By the late 18th century, some philosophers began to speak in defence of anarchy, seeing it as a preferable alternative to existing forms of tyranny. This lay the foundations for the development of anarchism, which advocates for the creation of anarchy through decentralisation and federalism.
Sources: en.wikipedia.org
As of the mid-2020s retatrutide remains investigational and is not an approved medicine in the United States or the European Union. It has been supplied mainly to participants in clinical trials. Labels and availability can change, so regulatory listings should be checked directly.
Dual agonists act at the GLP-1 and GIP receptors, whereas retatrutide adds glucagon receptor activity on the same peptide. This third activity is the main structural and pharmacological distinction discussed in the literature. Direct head-to-head comparisons remain limited.
Reports usually give the study code LY3437943 alongside the name, the dose in milligrams, and the week at which an endpoint was measured. Percent body-weight change is the most frequent headline measure. Units and populations vary, so comparisons across reports require care.
It is described as a single molecule that acts at three receptors: the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This triple activity distinguishes it from agents that target one or two of these pathways.